Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$1.72 ▼ -0.02
(-1.15%)
MKT CAP: $8.0M • VOL: 10.2K
52W L $1 52W H $3
ROARABLE / RQD
E • 26/100
PIOTROSKI
3 / 9
BMRA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-05-31 | FY 2024
FILED 2025-05-31 | FY 2023
FILED 2024-05-31 |
|---|---|---|---|
| Revenue (Total Sales) | $4.5M | $5.3M | $5.4M |
| YoY Revenue Growth % | -16.2% | -1.9% | — |
| Gross Profit | $362.0K | $498.0K | — |
| Gross Margin % | 8.1% | 9.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$5.3M | -$5.1M | -$6.4M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$3.8M | -$5.0M | -$6.0M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$3.4M | -$3.8M | -$5.4M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$3.4M | -$3.8M | -$5.4M |
| FCF Margin % | -76.8% | -72.3% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $2.5M | $2.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $4.4M | $5.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BMRA.